Chen R, Suchard MA, Krumholz HM, et al. - This study was intended to correlate the real-world effectiveness and safety of angiotensin-converting enzyme (ACE) inhibitors vs angiotensin receptor blockers (ARBs) in the first-line treatment of hypertension. A retrospective, the new-user comparative cohort was designed to calculate hazard ratios using techniques to minimize residual confounding and bias, specifically large-scale propensity score adjustment, empirical calibration, and full transparency. Researchers enrolled all patients with hypertension initiating monotherapy with an ACE inhibitor or ARB between 1996 and 2018 across 8 databases from the United States, Germany, and South Korea. Fifty-one secondary and safety outcomes including angioedema, cough, syncope and electrolyte abnormalities were also studied. Across 8 databases, They distinguished 2,297,881 patients initiating treatment with ACE inhibitors and 673,938 patients with ARBs. The results revealed preferentially prescribing ARBs over ACE inhibitors when initiating treatment for hypertension.